Crossmark

Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses to treatment

Crossref DOI link: https://doi.org/10.1007/s10928-024-09950-7

Published Online: 2024-12-10

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gomeni, Roberto

Bressolle-Gomeni, F.
License Information

Text and Data Mining valid from 2024-12-10

Version of Record valid from 2024-12-10
More Information

Article History

Received: 31 July 2024

Accepted: 30 October 2024

First Online: 10 December 2024

Declarations

:

: RG and FBG were paid consultants to Mapi pharma, Otsuka pharmaceutical, Auitifony Therapeutics; Tris Pharma; Orexia Therapeutics; Sunovion Pharmaceuticals; Chemopharma; Supernus Pharmaceuticals; Ironshore Pharmaceutical; Exeltis Pharma; UCB Pharma; Universal Pharma; Teva Pharmaceuticals; 4SC AG; Alfasigma; Recordati; CeNeRx BioPharma; GlaxoSmithKline; ViiV Healthcare; Hoffman-LaRoche; Indivior; Johnson & Johnson Pharmaceutical Research & Development; Reckitt Benckiser; Relmada Therapeutics Inc.; KYE Pharmaceuticals; Orphan Europe; Singapore Agency for Science, Technology and Research (A*STAR); Amgen Inc; Allecra Therapeutics; NDA Regulatory Service AB; Gilead Science, Inc; Theravance Biopharma; Sensorion SA; AstraZeneca.

Document is current

Any future updates will be listed below